FIELD: medicine, pharmacy.
SUBSTANCE: invention relates to producing medicinal agents and to a method for treatment of obesity. For production of medicinal agents amyline or amyline agonists of the definite chemical structure are used. Except for, invention proposes a method for treatment of obesity with using the specific amyline agonist - 25,28,29Pro-h-amyline in the developed for its doses and regimens of administration. Invention provides expanding assortment of medicinal agents used in treatment of obesity.
EFFECT: improved method of treatment.
11 cl, 8 tbl, 10 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHODS OF OBESITY TREATMENT | 1998 |
|
RU2207871C2 |
| ANALOG-AGONIST OF AMYLINE, ITS PHARMACEUTICALLY ACCEPTABLE SALTS, COMPOSITION EXHIBITING PROPERTIES OF AMYLINE AGONIST | 1992 |
|
RU2130463C1 |
| METHOD FOR INHIBITING GLUCAGON | 2000 |
|
RU2247575C9 |
| NEW COMPOSITIONS OF EXENDINE AGONISTS AND METHODS OF THEIR ADMINISTRATION | 2000 |
|
RU2242244C2 |
| METHODS FOR TREATMENT OF HYPERLIPIDEMIA IN PATIENTS WITH DIABETES BY INJECTION OF PCSK9 INHIBITOR | 2018 |
|
RU2772712C2 |
| POLYPEPTIDES | 2012 |
|
RU2669999C2 |
| INSULIN ANALOGUES | 2017 |
|
RU2769476C2 |
| SELECTION OF PATIENTS WITH HEADACHE SUSCEPTIBLE TO ANTIBODIES AGAINST CALCITONIN GENE-RELATED PEPTIDE | 2018 |
|
RU2770066C2 |
| AGONISTIC ANTIBODY TO LEPTIN RECEPTOR FOR USE IN TREATMENT OF METABOLISM DISORDERS OR HYPOLEPTINEMIA | 2019 |
|
RU2812670C2 |
| METHODS FOR TREATMENT OF SEVERE INSULIN RESISTANCE BY INTERRUPTING GLUCAGON RECEPTOR SIGNAL TRANSMISSION | 2017 |
|
RU2772508C2 |
